HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $21 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and maintains $21 price target.
Last updated: 2026-11-18 19:39:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Nuvation Bio Inc. (NUVB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $3.88, with a market capitalization of $1.36B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.79 to $9.75. This page covers its latest market performance, valuation, price trends and company information.
$1.36B | |
$3.92 | |
$4.09 | |
$3.82 | |
$3.90 | |
3.64M | |
5.15M | |
-- | |
$9.75 | |
$3.79 | |
-- | |
2026-09-30 |
Nuvation Bio Inc. (NUVB) is currently trading at $3.88 as of 2026-11-18 19:22:57, down 0.13% ($0.00) from the previous close of $3.90
During today's regular trading session, NUVB has traded between $3.82 and $4.09, with a trading volume of 3.64M shares. The current price is near the lower end of today's range.
Over the past seven days, Nuvation Bio Inc. (NUVB) moved from $4.35 to $3.88, representing a decline of 10.92% ($0.47).
The stock traded between $3.79 and $4.43 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 4.89 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 1.5%
NUVB is currently trading at $3.88, placing it 1.5% of the way from its 52-week low of $3.79 to its 52-week high of $9.75. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 310 |
| Exchange | NYSE |
| Company Website |
Latest news related to Nuvation Bio Inc. and NUVB stock.
HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and maintains $21 price target.
Four biotechnology companies presented clinical findings and emerging treatment approaches for brain cancers at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia. NeOnc Technologies is preparing for FDA meetings on two programs (NEO100 and NEO212), Cerenome is advancing REYOBIQ therapy and diagnostic tools, Nuvation Bio is expanding data on safusidenib for IDH1-mutant gliomas, and Jazz Pharmaceuticals is progressing dordaviprone through Phase 3 trials for rare brain cancers.
Eligible investors can buy real shares of Nuvation Bio Inc. (NUVB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to NUVB, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between NUVB shares and USD.
NUVB Shares to USD
1.00 NUVB shares = 3.875 USD
Calculations are estimates based on the latest available price and are for reference only.